Search | VHL Search Portal

1.

Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.

Ozaki, Yukinori; Yokoe, Takamichi; Yoshinami, Tetsuhiro; Nozawa, Kazuki; Nishio, Hiroshi; Tsuchihashi, Kenji; Ichihara, Eiki; Miura, Yuji; Endo, Makoto; Yano, Shingo; Maruyama, Dai; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ito, Mamoru; Baba, Eishi; Ochi, Nobuaki; Kubo, Toshio; Uchino, Keita; Kimura, Takahiro; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi.

Int J Clin Oncol ; 29(5): 551-558, 2024 May.

Article in English | MEDLINE | ID: mdl-38526621

2.

Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.

Kimura, Shoji; Shigeta, Keisuke; Tamura, Shingo; Uchino, Keita; Kimura, Takahiro; Ozaki, Yukinori; Nishio, Hiroshi; Tsuchihashi, Kenji; Ichihara, Eiki; Endo, Makoto; Yano, Shingo; Maruyama, Dai; Yoshinami, Tetsuhiro; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ito, Mamoru; Baba, Eishi; Ochi, Nobuaki; Kubo, Toshio; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi; Miura, Yuji.

Int J Clin Oncol ; 29(5): 559-563, 2024 May.

Article in English | MEDLINE | ID: mdl-38538963

3.

Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.

Uchino, Keita; Tamura, Shingo; Kimura, Shoji; Shigeta, Keisuke; Kimura, Takahiro; Ozaki, Yukinori; Nishio, Hiroshi; Tsuchihashi, Kenji; Ichihara, Eiki; Endo, Makoto; Yano, Shingo; Maruyama, Dai; Yoshinami, Tetsuhiro; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ito, Mamoru; Baba, Eishi; Ochi, Nobuaki; Kubo, Toshio; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi; Miura, Yuji.

Int J Clin Oncol ; 29(5): 545-550, 2024 May.

Article in English | MEDLINE | ID: mdl-38517658

4.

Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.

Tsuchihashi, Kenji; Ito, Mamoru; Okumura, Yuta; Nio, Kenta; Ozaki, Yukinori; Nishio, Hiroshi; Ichihara, Eiki; Miura, Yuji; Endo, Makoto; Yano, Shingo; Maruyama, Dai; Yoshinami, Tetsuhiro; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ochi, Nobuaki; Kubo, Toshio; Uchino, Keita; Kimura, Takahiro; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi; Baba, Eishi.

Int J Clin Oncol ; 29(6): 700-705, 2024 Jun.

Article in English | MEDLINE | ID: mdl-38696053

5.

Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.

Ito, Mamoru; Okumura, Yuta; Nio, Kenta; Baba, Eishi; Ozaki, Yukinori; Nishio, Hiroshi; Ichihara, Eiki; Miura, Yuji; Endo, Makoto; Yano, Shingo; Maruyama, Dai; Yoshinami, Tetsuhiro; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ochi, Nobuaki; Kubo, Toshio; Uchino, Keita; Kimura, Takahiro; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi; Tsuchihashi, Kenji.

Int J Clin Oncol ; 29(6): 689-699, 2024 Jun.

Article in English | MEDLINE | ID: mdl-38578596

6.

Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.

Yoshinami, Tetsuhiro; Nozawa, Kazuki; Yokoe, Takamichi; Ozaki, Yukinori; Nishio, Hiroshi; Tsuchihashi, Kenji; Ichihara, Eiki; Miura, Yuji; Endo, Makoto; Yano, Shingo; Maruyama, Dai; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ito, Mamoru; Baba, Eishi; Ochi, Nobuaki; Kubo, Toshio; Uchino, Keita; Kimura, Takahiro; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi.

Int J Clin Oncol ; 29(6): 681-688, 2024 Jun.

Article in English | MEDLINE | ID: mdl-38649648

7.

Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.

Najima, Yuho; Maeda, Tomoya; Kamiyama, Yutaro; Nakao, Shinji; Ozaki, Yukinori; Nishio, Hiroshi; Tsuchihashi, Kenji; Ichihara, Eiki; Miumra, Yuji; Endo, Makoto; Maruyama, Dai; Yoshinami, Tetsuhiro; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ito, Mamoru; Baba, Eishi; Ochi, Nobuaki; Kubo, Toshio; Uchino, Keita; Kimura, Takahiro; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi; Yano, Shingo.

Int J Clin Oncol ; 2024 May 17.

Article in English | MEDLINE | ID: mdl-38755516

8.

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.

Ichihara, Eiki; Ochi, Nobuaki; Makimoto, Go; Kudo, Kenichiro; Harada, Daijiro; Ozaki, Yukinori; Nishio, Hiroshi; Tsuchihashi, Kenji; Miura, Yuji; Endo, Makoto; Yano, Shingo; Maruyama, Dai; Yoshinami, Tetsuhiro; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ito, Mamoru; Baba, Eishi; Uchino, Keita; Kimura, Takahiro; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi; Kubo, Toshio.

Int J Clin Oncol ; 29(4): 355-362, 2024 Apr.

Article in English | MEDLINE | ID: mdl-38353907

9.

Real-world data analysis of perioperative chemotherapy patterns, G-CSF use, and FN status in patients with early breast cancer.

Shibata, Nobuhiro; Yoshinami, Tetsuhiro; Tamaki, Kentaro; Nukada, Tomoyuki; Ohno, Shinji.

Breast Cancer Res Treat ; 201(2): 265-273, 2023 Sep.

Article in English | MEDLINE | ID: mdl-37410318

10.

Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).

Kobayashi, Kokoro; Masuda, Norikazu; Mizuno, Toshiro; Miura, Kayo; Tokuda, Yutaka; Yoshinami, Tetsuhiro; Kawaguchi, Hidetoshi; Ohtani, Shoichiro; Saeki, Toshiaki; Toi, Masakazu; Takeuchi, Masahiro; Ito, Yoshinori.

Breast Cancer Res Treat ; 201(3): 409-415, 2023 Oct.

Article in English | MEDLINE | ID: mdl-37480384

11.

Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).

Yamamoto, Yutaka; Iwata, Hiroji; Taira, Naruto; Masuda, Norikazu; Takahashi, Masato; Yoshinami, Tetsuhiro; Ueno, Takayuki; Toyama, Tatsuya; Yamanaka, Takashi; Takano, Toshimi; Kashiwaba, Masahiro; Tsugawa, Koichiro; Hasegawa, Yoshie; Tamura, Kenji; Tada, Hiroshi; Hara, Fumikata; Fujisawa, Tomomi; Niikura, Naoki; Saji, Shigehira; Morita, Satoshi; Toi, Masakazu; Ohno, Shinji.

Cancer Sci ; 113(9): 3169-3179, 2022 Sep.

Article in English | MEDLINE | ID: mdl-35754298

12.

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).

Yamashita, Toshinari; Kawaguchi, Hidetoshi; Masuda, Norikazu; Kitada, Masahiro; Narui, Kazutaka; Hattori, Masaya; Yoshinami, Tetsuhiro; Matsunami, Nobuki; Yanagihara, Kazuhiro; Kawasoe, Teru; Nagashima, Takeshi; Bando, Hiroko; Yano, Hiroshi; Hasegawa, Yoshie; Nakamura, Rikiya; Kashiwaba, Masahiro; Morita, Satoshi; Ohno, Shinji; Toi, Masakazu.

Invest New Drugs ; 39(1): 217-225, 2021 02.

Article in English | MEDLINE | ID: mdl-32833136

13.

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).

Nakayama, Takahiro; Yoshinami, Tetsuhiro; Yasojima, Hiroyuki; Kittaka, Nobuyoshi; Takahashi, Masato; Ohtani, Shoichiro; Kim, Seung Jin; Kurakami, Hiroyuki; Yamamoto, Naoko; Yamada, Tomomi; Takata, Takehiko; Masuda, Norikazu.

BMC Cancer ; 21(1): 795, 2021 Jul 09.

Article in English | MEDLINE | ID: mdl-34238257

14.

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.

Iwasa, Tsutomu; Tsurutani, Junji; Watanabe, Satomi; Kato, Ryoji; Mizuno, Yutaka; Kojima, Yasuyuki; Takashima, Tsutomu; Matsunami, Nobuki; Morimoto, Takashi; Yamamura, Jun; Ohtani, Shoichiro; Tanabe, Yuko; Yoshinami, Tetsuhiro; Takano, Toshimi; Komoike, Yoshifumi; Nakagawa, Kazuhiko.

BMC Cancer ; 19(1): 962, 2019 Oct 16.

Article in English | MEDLINE | ID: mdl-31619197

15.

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

Yamamoto, Yutaka; Iwata, Hiroji; Ueno, Takayuki; Taira, Naruto; Kashiwaba, Masahiro; Takahashi, Masato; Tada, Hiroshi; Tsugawa, Koichiro; Toyama, Tatsuya; Niikura, Naoki; Hara, Fumikata; Fujisawa, Tomomi; Yoshinami, Tetsuhiro; Saji, Shigehira; Takano, Toshimi; Masuda, Norikazu; Morita, Satoshi; Toi, Masakazu; Ohno, Shinji.

Jpn J Clin Oncol ; 48(9): 855-859, 2018 Sep 01.

Article in English | MEDLINE | ID: mdl-30020510

16.

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.

Watanabe, Junichiro; Ito, Yoshinori; Ohsumi, Shozo; Mizutani, Mitsuhiro; Tashiro, Hideya; Sakurai, Kenichi; Takahashi, Masato; Saito, Tsuyoshi; Tsurutani, Junji; Mukai, Hirofumi; Yoshinami, Tetsuhiro; Takao, Shintaro; Yamamoto, Yasuhisa; Matsuoka, Toshiyuki; Iwase, Hirotaka; Iwata, Hiroji; Nakamura, Seigo; Saeki, Toshiaki.

Invest New Drugs ; 35(6): 791-799, 2017 12.

Article in English | MEDLINE | ID: mdl-28660549

17.

[â¢. T-DM1 in Residual Disease-Guided Approach].

Yoshinami, Tetsuhiro.

Gan To Kagaku Ryoho ; 48(12): 1454-1457, 2021 Dec.

Article in Japanese | MEDLINE | ID: mdl-34911911

18.

[A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer].

Shingai, Tatsushi; Sakai, Daisuke; Sugimoto, Naotoshi; Yoshinami, Tetsuhiro; Yagi, Toshinari; Yamamoto, Sachiko; Takeuchi, Yoji; Higashino, Koji; Noura, Shingo; Ohue, Masayuki; Yano, Masahiko.

Gan To Kagaku Ryoho ; 42(2): 195-9, 2015 Feb.

Article in Japanese | MEDLINE | ID: mdl-25743138

19.

Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy.

Yoshinami, Tetsuhiro.

Breast Cancer ; 2024 Apr 23.

Article in English | MEDLINE | ID: mdl-38649655

20.

Prognostic value of serum tartrateresistant acid phosphatase5b for bone metastasis in patients with resectable breast cancer.

Shimoda, Masafumi; Sato, Yasufumi; Abe, Kaori; Masunaga, Nanae; Tsukabe, Masami; Yoshinami, Tetsuhiro; Sota, Yoshiaki; Miyake, Tomohiro; Tanei, Tomonori; Shimazu, Kenzo.

Oncol Lett ; 27(6): 250, 2024 Jun.

Article in English | MEDLINE | ID: mdl-38638841

VHL Search Portal

Information and Knowledge for Health

Config filters

Your selection (0)

Export format:

Export: